Skip to main content

Table 8 Basecase results

From: Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece

  Strategy 1 Strategy 2 Difference (strategy 1 vs. strategy 2)
Total costs €10,003 €10,077 −€74
QALYs 6.30 6.19 0.11
Life years 8.07 7.96 0.11
ICER (cost per QALY gained)    Dominant
ICER (cost per LY gained)    Dominant